Japanese encephalitis is a serious disease found commonly throughout Asia. It is caused by the "JE virus", and is transmitted by infected mosquitoes.
The majority of infections are "asymptomatic" (show no symptoms); clinical disease develops in 1 in every 50-1,000 people infected. Over 50,000 clinical cases are reported worldwide each year.
If you are travelling to Asia on vacation or business, you may be at risk.
While virus-carrying mosquitoes are usually found in more rural areas, the virus can also be contracted in or near cities. Risk of infection can be seasonal, or occur throughout most of the year.
JE is well recognized beyond Japan, and is present in most Asian countries, including many popular travel destinations.
IXIARO® is a vaccine against the JE virus, used in people 18 years and older who live in or travel to areas where JE is common or seasonal. It is administered as two injections: the first on a selected date; the second, 28 days later.
In clinical studies, IXIARO® was shown to offer protection against the JE virus in as little as seven days after the second injection. The full duration of protection is unknown. Your travel health specialist will advise of the need for a booster dose.
Vaccination is recommended for travellers
to JE endemic/epidemic areas during
the risk season and spending:*
You may be covered for the IXIARO® vaccine with your private insurance.
Contact your insurance provider and give the DIN (drug identification number) below to find out.
IXIARO® DIN: 02333279
Find a vaccinating clinic offering the Japanese encephalitis vaccine
IXIARO® is a vaccine to help prevent Japanese encephalitis (JE); it is not used to treat the disease or its complications once they develop. IXIARO® is not recommended for use in persons below 18 years of age.
Individuals with the following conditions should discuss vaccination with their physician: pregnant or breastfeeding women; persons with a bleeding disorder, or abnormal bruising; persons with fever (temp. > 37.8°C); immunosuppressed persons or individuals on cancer treatment.
As with all injectable vaccines, appropriate medical treatment and supervision should always be available to treat rare cases of anaphylactic reactions following the administration of the vaccine. IXIARO® must never be injected into a vein or any blood vessel. As with any other vaccine, vaccination with IXIARO® may not result in protection in all cases. IXIARO® will not protect against encephalitis caused by other microorganisms. Like other intramuscular injections, this vaccine should not be administered intramuscularly to persons with thrombocytopenia, hemophilia or other bleeding disorders.
If your immune system does not work properly (immunodeficiency) or you are taking medicines affecting your immune system (such as a medicine called cortisone or cancer medicine), protection may not be as expected.
Other common side effects include nausea, influenza-like illness, fever, tiredness, and injection site reactions. Uncommon side effects include vomiting, skin rash, changes in lymph nodes, migraine and dizziness.
Visit valneva.ca to view the Consumer Information leaflet for IXIARO®.
Copyright © 2017 VALNEVA Canada Inc.
All trademarks used under license.